Company / Depreciation & Amortization
Mineralys Therapeutics, Inc. Depreciation & Amortization History
FY2023-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Depreciation & Amortization
$43.0K
FY2024
5-year range
$0 / $43.0K
FY2023-FY2024
Trend
-
vs FY2023
Sector context
#164 of 168
Health Care
What the data says
Among 168 Health Care companies, Mineralys Therapeutics, Inc. is in the top 2% for depreciation & amortization.
Based on SEC 10-K filings.
$43,000 in FY2024.
Health Care sector context is included.
Depreciation & Amortization over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 2% in Health CareTop 2% of 168This company $43.0K Sector average $212.9M
▼
-100.0% below sector average
Key checks
Key Insights
- Ranks #164 out of 168 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 3.25 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Depreciation & AmortizationValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $43.0K | - |
| FY2023 | $0 | - |
| FY2022 | - | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026